Natural killer cell (<scp>NK</scp>) subsets and <scp>NK</scp>‐like <scp>T</scp>‐cell populations in acute myeloid leukemias and myelodysplastic syndromes

Aggarwal, Nidhi; Swerdlow, Steven H.; TenEyck, S. P.; Boyiadzis, Michael; Felgar, Raymond E.

doi:10.1002/cyto.b.21349

Cited by 48 publications

(51 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this regard, Chretien et al (42) compared the presence of five different stages of NK cell development (CD56 high , CD56 low /KIR − /CD57 − , CD56 low /KIR + /CD57 − , CD56 low /KIR − /CD57 + , and CD56 low /KIR + /CD57 + ) in the PB of AML patients and found that one-third of the patients exhibited a significant increase in the proportion of the more mature CD56 low /KIR + /CD57 + NK cells at the expenses of more immature CD56 high NK cell subset. In addition, a recent study on NK cells from the BM of AML patients showed a reduced frequency of the more mature CD56 low CD16/57 high NK cell subset that did not correlate with a good prognosis (43). Collectively, these findings, although suggestive of a possible influence of AML cells on NK cell development, are still incomplete, as BM and PB NK cell subsets from the same patient have not been examined, and the possibility that the observed phenotype is due to a preferential migration of more mature CD56 low /KIR + /CD57 + NK cells from BM to PB is still open (56).…”

Section: Nk Cell Subsets In Hematological Malignanciesmentioning

confidence: 99%

Role of Distinct Natural Killer Cell Subsets in Anticancer Response

et al. 2017

View full text Add to dashboard Cite

Natural killer (NK) cells, the prototypic member of innate lymphoid cells, are important effectors of anticancer immune response. These cells can survey and control tumor initiation due to their capability to recognize and kill malignant cells and to regulate the adaptive immune response via cytokines and chemokines release. However, several studies have shown that tumor-infiltrating NK cells associated with advanced disease can have profound functional defects and display protumor activity. This evidence indicates that NK cell behavior undergoes crucial alterations during cancer progression. Moreover, a further level of complexity is due to the extensive heterogeneity and plasticity of these lymphocytes, implying that different NK cell subsets, endowed with specific phenotypic and functional features, may be involved and play distinct roles in the tumor context. Accordingly, many studies reported the enrichment of selective NK cell subsets within tumor tissue, whereas the underlying mechanisms are not fully elucidated. A malignant microenvironment can significantly impact NK cell activity, by recruiting specific subpopulations and/or influencing their developmental programming or the acquisition of a mature phenotype; in particular, neoplastic, stroma and immune cells, or tumor-derived factors take part in these processes. In this review, we will summarize and discuss the recently acquired knowledge on the possible contribution of distinct NK cell subsets in the control and/or progression of solid and hematological malignancies. Moreover, we will address emerging evidence regarding the role of different components of tumor microenvironment on shaping NK cell response.

show abstract

Section: Nk Cell Subsets In Hematological Malignanciesmentioning

confidence: 99%

Role of Distinct Natural Killer Cell Subsets in Anticancer Response

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The activation and function of natural killer (NK) cells exert important cytotoxic activity in response to MDS and other myeloid neoplasms, but their function is reduced in high risk MDS. [6, 47] Moreover, NK cells from MDS patients lose in vitro anti-leukemic activity due to a TNFα-induced IL-32 secretion from stromal cells. [48] In this study, IL-32 directly inhibited the activity of NK cells, and it was found that stromal cells from MDS patients produced higher levels of IL-32.…”

Section: Introductionmentioning

confidence: 99%

Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes

Ivy

Ferrell

2018

Curr Hematol Malig Rep

View full text Add to dashboard Cite

Immune alterations in MDS are complex, heterogeneous, and intertwined with clonal hematopoiesis and stromal cell dysfunction. Inflammation in MDS proceeds as a vicious cycle, mediated in large part by secreted factors, which induce cell death and activate innate immune signaling. Therapeutic targeting of this variable immune dysregulation has led to modest responses thus far, but incorporation of the growing repertoire of immunotherapy brings new potential for improved outcomes. The immune milieu is variable across the spectrum of MDS subtypes, with a changing balance of inflammatory and suppressive cellular forces from low- to high-risk disease.

show abstract

“…The Pittsburgh Group Immune Dysregulation in Myelodysplastic Syndromes: Pathogenetic-Pathophysiologic Aspects and Clinical Consequences http://dx.doi.org/10.5772/64618 reported different marrow frequencies of NK and NK T cells in MDS and AML. In MDS they did not find numerical impairment of the NK-cell population, but a significant decrease in mature CD56 dim CD16+CD57 bright cells, which had great prognostic significance for survival [58]. Other groups have reported increased intracellular granzyme-B levels in the NK cells of MDS patients [59].…”

Section: Nk Cell Abnormalitiesmentioning

confidence: 89%

Immune Dysregulation in Myelodysplastic Syndromes: Pathogenetic-Pathophysiologic Aspects and Clinical Consequences

Symeonidis¹,

Kouraklis-Symeonidis²

2016

Myelodysplastic Syndromes

View full text Add to dashboard Cite

Myelodysplastic syndromes are clonal hematopoietic stem cell disorders, in which the immune system plays a substantial pathogenetic role. Patients manifest frequent infections, mainly attributed to neutropenia, but sometimes opportunistic pathogens are isolated in non-neutropenic patients. They also exhibit autoimmune diseases or syndromes with a background of immune activation and various abnormalities of Tlymphocytes, "-lymphocytes, and NK cells. The most typical profile includes reduced total T lymphocytes mainly CD + helper T-cells, resulting in decrease or inversion of the CD /CD cell ratio and impaired NK cell function. Many TH direction cytokines, and particularly sIL-R, IL-, and TNF-are usually found increased in the serum and bone marrow, which have been strongly associated with advanced disease, anemia, and other disease-related features. Clonal origin of lymphocytes has been confirmed only in few cases. Mixed lymphocyte cultures and genomic assays have shown severely impaired immunoregulatory abnormalities, probably induced by the hematopoietic cells. In a minority of patients, immune activation is capable to prevent or delay clonal expansion, but these patients have more profound hematopoietic impairment. Immunosuppressive treatment may not only relieve the autoimmune manifestations but also improve hematopoiesis. However, this kind of treatment is not well tolerated, is associated with severe infections, and in some cases may enhance "ML evolution.

show abstract

Natural killer cell (NK) subsets and NK‐like T‐cell populations in acute myeloid leukemias and myelodysplastic syndromes

Cited by 48 publications

References 49 publications

Role of Distinct Natural Killer Cell Subsets in Anticancer Response

Role of Distinct Natural Killer Cell Subsets in Anticancer Response

Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes

Immune Dysregulation in Myelodysplastic Syndromes: Pathogenetic-Pathophysiologic Aspects and Clinical Consequences

Contact Info

Product

Resources

About